全文获取类型
收费全文 | 1615170篇 |
免费 | 132171篇 |
国内免费 | 2647篇 |
专业分类
耳鼻咽喉 | 21868篇 |
儿科学 | 53462篇 |
妇产科学 | 46637篇 |
基础医学 | 229389篇 |
口腔科学 | 47396篇 |
临床医学 | 142259篇 |
内科学 | 317671篇 |
皮肤病学 | 34532篇 |
神经病学 | 131171篇 |
特种医学 | 65143篇 |
外国民族医学 | 474篇 |
外科学 | 245968篇 |
综合类 | 39874篇 |
现状与发展 | 3篇 |
一般理论 | 564篇 |
预防医学 | 123688篇 |
眼科学 | 36789篇 |
药学 | 122052篇 |
3篇 | |
中国医学 | 2991篇 |
肿瘤学 | 88054篇 |
出版年
2018年 | 15217篇 |
2016年 | 13263篇 |
2015年 | 15378篇 |
2014年 | 21119篇 |
2013年 | 31984篇 |
2012年 | 43449篇 |
2011年 | 45676篇 |
2010年 | 26831篇 |
2009年 | 25793篇 |
2008年 | 43724篇 |
2007年 | 46056篇 |
2006年 | 46783篇 |
2005年 | 45378篇 |
2004年 | 44745篇 |
2003年 | 42741篇 |
2002年 | 41769篇 |
2001年 | 75848篇 |
2000年 | 78451篇 |
1999年 | 66537篇 |
1998年 | 17851篇 |
1997年 | 16412篇 |
1996年 | 16382篇 |
1995年 | 16074篇 |
1994年 | 15132篇 |
1993年 | 14284篇 |
1992年 | 55512篇 |
1991年 | 53874篇 |
1990年 | 52640篇 |
1989年 | 50930篇 |
1988年 | 47290篇 |
1987年 | 46636篇 |
1986年 | 44359篇 |
1985年 | 42929篇 |
1984年 | 32115篇 |
1983年 | 27631篇 |
1982年 | 16213篇 |
1981年 | 14524篇 |
1980年 | 13619篇 |
1979年 | 30521篇 |
1978年 | 21117篇 |
1977年 | 17813篇 |
1976年 | 16728篇 |
1975年 | 17610篇 |
1974年 | 21531篇 |
1973年 | 20695篇 |
1972年 | 18889篇 |
1971年 | 17799篇 |
1970年 | 16317篇 |
1969年 | 15295篇 |
1968年 | 13977篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
961.
Background:
The results of a pilot colorectal cancer screening programme by biennial immunochemical faecal occult blood test (FOBT) are reported.Methods:
All residents aged between 50 and 69 years in the Italian province of Lecco were invited to have a FOBT. Those with a positive result were offered colonoscopy. FOBT uptake and compliance with colonoscopy were assessed. Detection rate and positive predictive value (PPV) for cancer and adenoma were calculated. Tumour stages were compared between screen‐detected cancers and other colorectal cancers diagnosed within the target age group.Results:
Some 38 693 (49·6 per cent) of 78 083 individuals had a FOBT and 2392 (6·2 per cent) had a positive result. Colorectal cancer was diagnosed in 4·6 per cent and advanced adenoma in 32·7 per cent. PPVs were 4·0 per cent for cancer, 28·1 per cent for advanced adenoma and 36·6 per cent for any adenoma. There was a significant difference in incidence of stage III/IV disease between screened and non‐screened cohorts. Compliance for colonoscopy was 92·0 per cent. Major determinants of compliance were age less than 59 years, female sex, high education level and non‐manual work.Conclusion:
These results justify extension of colorectal cancer screening to other regions of Italy. Copyright © 2009 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd. 相似文献962.
Michael Bohnsack D.B. Saris J. Vanlauwe F. Almqvist J. Victor J. Bellemans R. Verdonk F.P. Luyten 《Sport》2009,25(2):137-138
963.
964.
965.
966.
967.
968.
Rajesh Venkataraman Karthik R. Vaidyanathan Madhu N. Sankar Kotturathu M. Cherian 《Journal of cardiac surgery》2009,24(4):443-445
Abstract Dissection of the pulmonary autograft is an extremely rare complication requiring emergent treatment as there is a chance of rupture and proximal aortic involvement. The autograft dissection can involve the aortic annulus, causing separation of leaflets from the annulus in addition to causing annular dilatation, thereby precluding resuspension of leaflets. The usual treatment in such cases is to perform the Bentall procedure, which involves placing a valved conduit (usually mechanical valve) and thereby necessitating anticoagulation. This report describes a case of successful valve-sparing aortic root replacement following the Ross procedure with dissection of autograft. 相似文献
969.
970.
J.-P. Ortonne A. Taïeb A.D. Ormerod† D. Robertson‡ J. Foehl‡ R. Pedersen‡ C. Molta‡ B. Freundlich‡ 《The British journal of dermatology》2009,161(5):1190-1195
Background Patients with psoriasis experience remission and gradual reappearance of erythematous and scaly plaques and require individualized treatment over time. A goal of psoriasis treatment is to provide optimal efficacy with a flexible therapeutic regimen that may include treatment pauses.
Objectives To determine whether patients receiving initial treatment with etanercept who then pause therapy would subsequently recapture response during re-treatment.
Patients and methods A post-hoc analysis of 226 patients with moderate-to-severe psoriasis from a large multicentre trial was performed. Patients had received etanercept 50 mg twice weekly subcutaneously until a target clinical response had been achieved, then had paused treatment and eventually relapsed. They were then re-treated with etanercept 25 mg twice weekly. The number of patients recapturing a Physician Global Assessment (PGA) of psoriasis rating of ≤ 2 (clear, almost clear or mild) on first re-treatment was assessed. Patient satisfaction during the initial treatment and first re-treatment period was also determined.
Results A total of 187 (83%) patients recaptured the target clinical response of a PGA of ≤ 2 after re-treatment. The majority of patients [219 of 226 (97%)] reported satisfaction with etanercept re-treatment. No new safety concerns emerged during re-treatment.
Conclusions In this post-hoc analysis, patients with psoriasis who were re-treated with etanercept 25 mg twice weekly effectively recaptured clinical responses that patients found satisfactory. A flexible treatment option is available to dermatologists and patients for individualized care. 相似文献
Objectives To determine whether patients receiving initial treatment with etanercept who then pause therapy would subsequently recapture response during re-treatment.
Patients and methods A post-hoc analysis of 226 patients with moderate-to-severe psoriasis from a large multicentre trial was performed. Patients had received etanercept 50 mg twice weekly subcutaneously until a target clinical response had been achieved, then had paused treatment and eventually relapsed. They were then re-treated with etanercept 25 mg twice weekly. The number of patients recapturing a Physician Global Assessment (PGA) of psoriasis rating of ≤ 2 (clear, almost clear or mild) on first re-treatment was assessed. Patient satisfaction during the initial treatment and first re-treatment period was also determined.
Results A total of 187 (83%) patients recaptured the target clinical response of a PGA of ≤ 2 after re-treatment. The majority of patients [219 of 226 (97%)] reported satisfaction with etanercept re-treatment. No new safety concerns emerged during re-treatment.
Conclusions In this post-hoc analysis, patients with psoriasis who were re-treated with etanercept 25 mg twice weekly effectively recaptured clinical responses that patients found satisfactory. A flexible treatment option is available to dermatologists and patients for individualized care. 相似文献